Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study

BACKGROUND: The CHAARTED and LATITUDE trials demonstrated a prolonged overall survival (OS) for metastatic hormone-naïve prostate cancer (mHNPC) patients who receive up-front docetaxel or abiraterone acetate. These studies used their own risk criteria: CHAARTED trial defines high- and low-volume dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahara, Takashi, Yoneyama, Shuko, Ohno, Yoshio, Iizuka, Junpei, Hashimoto, Yasunobu, Tsumura, Hideyasu, Tabata, Ken-ichi, Nakagami, Yoshihiro, Tanabe, Kazunari, Iwamura, Masatsugu, Uemura, Hiroji, Miyoshi, Yasuhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352129/
https://www.ncbi.nlm.nih.gov/pubmed/32714984
http://dx.doi.org/10.1155/2020/7804932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352129/
https://www.ncbi.nlm.nih.gov/pubmed/32714984
http://dx.doi.org/10.1155/2020/7804932

Ejemplares similares